 Home > Active Ingredient News > Antitumor Therapy > J Immuno Cancer: A Comparative Analysis of Phase III Clinical Trials for The Treatment of Head and Neck Squamous Cell Carcinoma Patients with Anti-PD1 Single Drug

J Immuno Cancer: A Comparative Analysis of Phase III Clinical Trials for The Treatment of Head and Neck Squamous Cell Carcinoma Patients with Anti-PD1 Single Drug

 Last Update: 2020-07-13
 Source: Internet
 Author: User

Tags

chemotherapy drugs classification

pdms design group

treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Two Phase III clinical trials (CheckMate 141 and KEYNOTE 040) have independently demonstrated that the total lifetime (OS) of patients with failed platinum-based treatment can be improved with anti-PD1 monotorth therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC)compared to standard care (SOC) chemotherapy monodrug (especially citoxitamitis, dositaor, or methotrexate), R/M HNSCC patients use nivolumab or pembrolizumab treatment to improve OS, the risk ratio (HR) 0.70 (95% CI 0.51-0.96; p - 0.01) and 0.80 (95% CI 0.65-0.98, p - 0.0161) respectivelyThe gains of OS were similar in the two studies, highlighting the role of anti-PD1 drugs in patients with R/M HNSCCOne of the significant differences between CheckMate 141 and KEYNOTE 040 was the OS observed in the control group SOC (the median of KEYNOTE 040 was 6.9 months and the median of CheckMate 141 was 5.1 months), which inadvertently set a high threshold in the biostatistical analysis of 040, so the clinical results of each patient in the analysis had an impactour comparative analysis of the two studies to identify potential factors in the control group that could affect the biostatistical results of clinical trials may have an impact on futureimmuno
therapeutic clinical trial design

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.